9 news items
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SEEL
16 May 24
diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
SEEL
14 May 24
targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ADVM
ANGH
20 Mar 24
downgraded the stock from Equal-Weight to Underweight and lowered its price target from $7.50 to $4.50.
Ontrak, Inc
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
CAL
CALX
CMTL
19 Mar 24
Outperform to Market Perform but raised its price target from $17 to $21.
Spire Global, Inc
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
ACMR
AFIB
ALHC
19 Mar 24
Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21.
SCWorx Corp
z2mlpl927ptl5j8pra1sqgb8 eovhkuvxixy3ddathzauenob5vjr1kv
CMTL
CNM
FUSN
19 Mar 24
. Also, Leerink Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21.
Spire
7sei5qh 6om6th2ojk85vakxhgmxog
ENVB
FUSN
GWAV
19 Mar 24
target from $17 to $21.
Enveric Biosciences, Inc
lk1q0o azi7d8as65w9re2hwnyxgqmbhk7ow7ecl1lpwmn
SEEL
19 Mar 24
of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. The activation of TFEB is an emerging therapeutic target
smgk07z f0p2
SEEL
19 Mar 24
in lysosomal and autophagy gene expression. The activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation
- Prev
- 1
- Next